Abstract

The advent of drug-eluting stents and drug-coated balloons have significantly improved the clinical outcome of patients with vascular occlusions. However, ischemic vascular disease remains the most common cause of death worldwide. Although the next generation of devices is aimed at improving the safety and efficacy of the treatment, current experimental methods are unable to capture the influence of atherosclerosis on these modalities. To address this, in our study, we use in-silico models to numerically evaluate the influence of an atheroma, nature of an excipient and discuss the possibility of an optimal therapeutic time. This study aims to demonstrate that the use of such computational models, could potentially lead to treatment modalities that are tailored to the needs of individual patients.

Biography

Karthic Anbalakan is a researcher at the National University of Singapore and has presented his findings at TCT-Connect: Transcatheter Cardiovascular Therapeutics and ICBME 2019. His research explores various interventional cardiovascular treatments, computational modelling, and experimental techniques.

X